Rithim Biologics®Inc. Announces Issuance of Its First US Patent Covering the Use of the DAAViS™ Catheter for Delivering Therapeutic Compounds to Combat Various Cardiac Disease States
July 25, 2022
Woodbine, MD, July 25, 2022--Rithim Biologics®, Inc. is excited to announce the issuance of its first patent, US 11,369,773 B2, covering TARGETED CARDIAC THERAPY using the company’s proprietary DAAViS Catheter™. The present invention relates to a targeted cardiac therapy device that can precisely deliver therapeutic compounds to desired locations on, around or within the heart of a patient, and methods of treating conduction system disease, sinus node dysfunction, atrial fibrillation, myocardial infarction, and heart failure, by delivering genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals and biologics.
J. Kevin Donahue, M.D., co-Founder of Rithim Biologics and a named inventor of the patent stated: “we are pleased with this patent issuance for the DAAViS catheter as it aids in providing future advanced tools for delivery of gene therapies to the heart’s surface in a less invasive technique.”
Ronald L. Anderson, President and co-founder of Rithim, noted: “this patent represents another large step forward in Rithim’s development as a company and for potential future treatment options for patients with rhythm disturbances such as atrial fibrillation, a $ 6 billion annual US healthcare burden.”
Rithim Biologics®, Inc. is a privately held, early-stage startup company developing surgical tools and kits for delivering gene therapies to treat tachycardias (fast heart rates) in humans. Initial efforts are targeting atrial fibrillation (AF) and more specifically those patients at risk for post-operative (cardiac) AF (POAF) combining KCNH2-G628 gene therapy development with proprietary instrumentation and kits for efficacious delivery in humans.
For further information contact:
Ronald L. Anderson, [email protected]
Rithim Biologics®Inc. Presents at 2020 BIO International Convention Digital
June 5, 2020
Woodbine, MD, June 5, 2020--Rithim Biologics®, Inc. is honored to be presenting at and attending the 2020 BIO International Convention Digital within the NIH Innovation Zone, June 8-12. Rithim’s co-Founders, Dr. Kevin Donahue and Ronald Anderson, will be presenting a 15-minute presentation on the company’s current efforts in delivering gene therapy to the heart. Initial product development targets the prevention of atrial fibrillation in a post-operative setting (POAF). POAF is an estimated $3 B burden on US healthcare and greater than $7 B on the world’s healthcare. Current products in development include the TheraKit™ inclusive of the cardiac gene therapy and either the SafeBrush™ for open heart applications or the DAAViS™ catheter system for less invasive cardiac surgical procedures.
Rithim Biologics® Adds World Class Talent to its Board of Directors with The Addition of Bob H. Katz
April 28, 2020
Woodbine, MD, Apr. 28, 2020--Rithim Biologics®, Inc. is pleased to announce the addition of Mr. Bob H. Katz to its Board of Directors effective March 1, 2020.
Bob is a proven serial life science start-up executive with a broad, multi-disciplinary background. He has excelled as an early stage specialist with unique R&D, Clinical, Regulatory and Operations successes. Mr. Katz’s background includes medical device and combination product (drug/device) development including implantables, durable medical equipment and disposables. He has been instrumental in successful PMA, IND, 510K and CE Marked product developments & regulatory approvals. His experiences span an impressive 36-year career in the fields of interventional cardiology, endovascular and vascular surgery, electrophysiology, ENT, women’s health & emergency medicine. Bob has a reputation for building effective and loyal teams and successful product introductions. He is self-driven with an entrepreneurial effort and venture fundraising experiences which have led to successful IPO and M&A outcomes. He is a named inventor on 20+ patents and has managed IP portfolios. Mr. Katz has served on the Board of Directors at ContraMed LLC and PinPointe USA, Inc., and in senior executive roles at ContraMed, LLC, PinPointe USA, Inc., Aptus Endosystems, Revivant Corporation, and Symphonix Devices, Inc. He is currently a Partner and Chief Technology Officer at Hybridge Medical, LLC.
Bob has earned his M.B.A. from the Friedt School of Business, Southeastern University; his M.S. in Biomedical Engineering from Boston University; a B.A. in Business Administration and a B.S. in Electrical Engineering both from Rutgers University.
“We are thrilled to have Bob bring his leadership and strategic and functional skills to our Board of Directors”, stated Ronald Anderson, Chairman.
Rithim Biologics®, Inc. is a privately held, early stage startup company developing surgical tools and kits for delivering gene therapies to treat tachycardias (fast heart rates) in humans. Initial efforts are targeting atrial fibrillation (AF) and more specifically those patients at risk for post-operative (cardiac) AF (POAF) combining KCNH2-G628 gene therapy development with proprietary instrumentation and kits for efficacious delivery in humans.
For further information contact:
Ronald Anderson, [email protected]